This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Reveille, J D Search for Related Content PubMed PubMed Citation Articles by Reveille, J D Social Bookmarking                         What's this?

Predictive value of autoantibodies for activity of systemic lupus erythematosus

Division of Rheumatology, The University of Texas, Houston Health Science Center at Houston, Houston, TX, USA, john.d.reveille{at}uth.tmc.edu

There is no serologic test that reliably measures disease activity in systemic lupus erythematosus (SLE). The ‘gold standard’ is the anti-dsDNA antibody test, which has been used as a marker of disease activity by clinicians in SLE for over 35 years. Anti-dsDNA antibodies perform best in those with lupus nephritis, specifically in the presence of a proliferative lesion [World Health Organization (WHO) class III or IV] on renal biopsy. In one recent meta-analysis, the mean positivelikelihood ratio of anti-dsDNA antibodies as a marker of disease activity in SLE was 4.14, implying the overall predictive effect was small. More recently autoantibodyassays have been developed that show greater promise in gauging SLE disease activity, specifically anti-nucleosome and anti-C1q antibodies (especially with renal disease activity). Other tests thought previously to be lacking in specificity that refinements in ELISA technology now render possibly useful include anti-heparan sulfate, anti-ssDNA and anti-Scl-70 autoantibodies. Other tests that as yet have not been shown to be as reliable (and therefore are not as useful in clinical practice for serial determinationto measure disease activity) include other anti-extractablenuclear antibodies (anti-Ro, La, Sm, RNP), anti-cardiolipinantibodies, and anti-nuclear cytoplasmic antibodies (ANCA). New technologies using proteomic determinations show promise as aids in the search for more reliable and feasible autoantibody determinations of disease activity in SLE.

Key Words: anti-dsDNA • autoantibodies • disease activity • systemic lupus erythematosus

Lupus, Vol. 13, No. 5, 290-297 (2004)
DOI: 10.1191/0961203303lu1015oa


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				D. H. Kono, M. K. Haraldsson, B. R. Lawson, K. M. Pollard, Y. T. Koh, X. Du, C. N. Arnold, R. Baccala, G. J. Silverman, B. A. Beutler, et al. Endosomal TLR signaling is required for anti-nucleic acid and rheumatoid factor autoantibodies in lupus PNAS, July 21, 2009; 106(29): 12061 - 12066. [Abstract] [Full Text] [PDF]

				M. J. Ryan Young Investigator Award Lecture of the APS Water and Electrolyte Homeostasis Section, 2008: The pathophysiology of hypertension in systemic lupus erythematosus Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2009; 296(4): R1258 - R1267. [Abstract] [Full Text] [PDF]

				J. Hanly The neuropsychiatric SLE SLICC inception cohort study Lupus, December 1, 2008; 17(12): 1059 - 1063. [PDF]

				A. Negron, M. Molina, A. Mayor, V. Rodriguez, and L. Vila Factors associated with metabolic syndrome in patients with systemic lupus erythematosus from Puerto Rico Lupus, April 1, 2008; 17(4): 348 - 354. [Abstract] [PDF]

				A. M. Bertoli, L. M. Vila, M. Apte, B. J. Fessler, H. M. Bastian, J. D. Reveille, G. S. Alarcon, and for the LUMINA Study Group Systemic lupus erythematosus in a multiethnic US cohort LUMINA LI: Anaemia as a predictor of disease activity and damage accrual Rheumatology, September 1, 2007; 46(9): 1471 - 1476. [Abstract] [Full Text] [PDF]

				A. Buhl, J. H. Metzger, N. H. H. Heegaard, P. von Landenberg, M. Fleck, and P. B. Luppa Novel Biosensor-Based Analytic Device for the Detection of Anti-Double-Stranded DNA Antibodies Clin. Chem., February 1, 2007; 53(2): 334 - 341. [Abstract] [Full Text] [PDF]

				M Ishii, Y Muramoto, H Kosaka, S Ohshima, T Mima, Y Katada, S Hirohata, and Y Saeki A serological switching from anti-dsDNA to anti-Sm antibodies coincided with severe clinical manifestations of systemic lupus erythematosus (hemophagocytosis, profundus and psychosis) Lupus, January 1, 2007; 16(1): 67 - 69. [PDF]

				L M Vila, M J Molina, A M Mayor, R A Peredo, M L Santaella, and S Vila Clinical and prognostic value of autoantibodies in Puerto Ricans with systemic lupus erythematosus Lupus, December 1, 2006; 15(12): 892 - 898. [Abstract] [PDF]

				G S Alarcon, J Calvo-Alen, G McGwin Jr, A G Uribe, S M A Toloza, J M Roseman, M Fernandez, B J Fessler, L M Vila, C Ahn, et al. Systemic lupus erythematosus in a multiethnic cohort: LUMINA XXXV. Predictive factors of high disease activity over time Ann Rheum Dis, September 1, 2006; 65(9): 1168 - 1174. [Abstract] [Full Text] [PDF]

				G. Rai, S. Ray, R. E. Shaw, P. F. DeGrange, R. G. Mage, and B. A. Newman Models of Systemic Lupus Erythematosus: Development of Autoimmunity Following Peptide Immunizations of Noninbred Pedigreed Rabbits J. Immunol., January 1, 2006; 176(1): 660 - 667. [Abstract] [Full Text] [PDF]

				J. Gentiletti, L. J. McCloskey, C. M. Artlett, J. Peters, S. A. Jimenez, and P. J. Christner Demonstration of Autoimmunity in the Tight Skin-2 Mouse: A Model for Scleroderma J. Immunol., August 15, 2005; 175(4): 2418 - 2426. [Abstract] [Full Text] [PDF]